Limited coverage criteria – risperidone microspheres

risperidone microspheres

12.5 mg/2 mL, 25 mg/2 mL, 37.5 mg/2 mL, 50 mg/2 mL injection                                                                   

For managing the manifestations of schizophrenia or related psychotic disorders (not dementia-related) in:

Patients who have tried oral risperidone, aripiprazole, or paliperidone PLUS at least one other antipsychotic agent AND continue to be inadequately controlled at maximally tolerated doses

OR

Patients who are currently receiving a conventional depot antipsychotic PLUS are experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia

OR

Patients with a history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations

Indefinite